<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543569</url>
  </required_header>
  <id_info>
    <org_study_id>0485-CL-U201</org_study_id>
    <nct_id>NCT00543569</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 4 arm (all active) study to determine the safety and efficacy of Alefacept in de
      novo kidney transplant recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review</measure>
    <time_frame>6 months</time_frame>
    <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Day 182 was used for the analyses at 6 months. Lost to follow-up or patients with missing outcomes were censored at their last follow up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at Month 6 and Month 12</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Patient survival is any participant who is known to be alive 6 months and 12 months after the skin closure date.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival at Month 6 and Month 12</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months and 12 months after the skin closure date. Graft loss was defined as patient death, retransplant, permanent return to dialysis (dialysis greater than 30 days) or transplant nephrectomy.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCAR at Month 12 Assessed by Local Review</measure>
    <time_frame>12 months</time_frame>
    <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Day 365 was used for the analyses at 12 months. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCAR at Month 6 and 12 Assessed by Central Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Rejection episodes were confirmed by biopsy by a central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Local Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Central Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Rejection episodes were confirmed by biopsy by the central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 4 in Glomerular Filtration Rate Estimated by the MDRD Method at Month 6 and Month 12</measure>
    <time_frame>Week 4, Month 6 and Month 12</time_frame>
    <description>The glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 4 in GFR by Iothalamate Clearance at Month 6</measure>
    <time_frame>Week 4 and Month 6</time_frame>
    <description>The glomerular filtration rate was measured directly using iothalamate clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 4 in Serum Creatinine at Month 6 and 12</measure>
    <time_frame>Week 4 and Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Local Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Efficacy failure is defined as death, graft failure (permanent return to dialysis [&gt;30 days] or retransplant), BCAR according to local review, or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Central Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Efficacy failure is defined as death, graft failure (permanent return to dialysis [&gt;30 days] or retransplant), BCAR according to central review, or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First BCAR Assessed by Local Review</measure>
    <time_frame>12 months</time_frame>
    <description>The time to first BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First BCAR Assessed by Central Review</measure>
    <time_frame>12 months</time_frame>
    <description>The time to first BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First T-cell Mediated BCAR Assessed by Local Review</measure>
    <time_frame>12 months</time_frame>
    <description>The time to first T-cell mediated BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First T-cell Mediated BCAR Assessed by Central Review</measure>
    <time_frame>12 months</time_frame>
    <description>The time to first T-cell mediated BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a T-cell mediated BCAR are included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Grade of T-cell Mediated Rejection Assessed by Local Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.
Grade IA: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising &gt;25% of the luminal area; Grade III: Cases with &quot;transmural&quot; arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Grade of T-cell Mediated Rejection as Assessed by Central Review</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.
Grade IA: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising &gt;25% of the luminal area; Grade III: Cases with &quot;transmural&quot; arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Treated Acute Rejection at Month 6 and Month 12</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Patients who received immunosuppressive medications for the treatment of suspected or BCAR were considered to have a clinically-treated acute rejection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-lymphocyte-treated Rejection at Months 6 and 12</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Participants with histologically proved Banff Grade II or III rejection could receive anti-rejection therapy with anti-lymphocyte antibodies per institutional protocol.
The use of anti-lymphocyte antibody therapy at any time during a suspected or proven rejection episode for the treatment of acute rejection was considered an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Multiple Rejection Episodes at Months 6 and 12</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>All participants were evaluated for the incidence of multiple rejection episodes (clinically treated and/or BCAR as assessed by the local reviewer) through 6 months and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Failure at Month 6 and 12</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Treatment failure was defined as death, graft loss, BCAR (local review), lost to follow-up or early discontinuation of treatment regimen. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Quality of Life Index Score Over Time</measure>
    <time_frame>Months 1, 3, 6, and 12</time_frame>
    <description>The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) symptom severity score. The GIQLI is a 36-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past 2 weeks on a scale from 0 (all of the time) to 4 (never). Possible overall scores ranged from 0 to 4, with higher scores indicating a better quality of life according to the different symptomatic criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale Scores Over Time</measure>
    <time_frame>Months 1, 3, 6, and 12</time_frame>
    <description>The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale Scores (GSRS). The GSRS a 15-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Tacrolimus/MMF/Basiliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alefacept QW/Tacrolimus/MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alefacept QW/Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alefacept QOW/Tacrolimus/MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alefacept</intervention_name>
    <description>Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.</description>
    <arm_group_label>Alefacept QW/Tacrolimus/MMF</arm_group_label>
    <arm_group_label>Alefacept QW/Tacrolimus</arm_group_label>
    <arm_group_label>Alefacept QOW/Tacrolimus/MMF</arm_group_label>
    <other_name>Amevive, ASP0485</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.</description>
    <arm_group_label>Tacrolimus/MMF/Basiliximab</arm_group_label>
    <arm_group_label>Alefacept QW/Tacrolimus/MMF</arm_group_label>
    <arm_group_label>Alefacept QW/Tacrolimus</arm_group_label>
    <arm_group_label>Alefacept QOW/Tacrolimus/MMF</arm_group_label>
    <other_name>Prograf, FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basiliximab</intervention_name>
    <description>Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.</description>
    <arm_group_label>Tacrolimus/MMF/Basiliximab</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.</description>
    <arm_group_label>Tacrolimus/MMF/Basiliximab</arm_group_label>
    <arm_group_label>Alefacept QW/Tacrolimus/MMF</arm_group_label>
    <arm_group_label>Alefacept QOW/Tacrolimus/MMF</arm_group_label>
    <other_name>CellCept, MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.</description>
    <arm_group_label>Tacrolimus/MMF/Basiliximab</arm_group_label>
    <arm_group_label>Alefacept QW/Tacrolimus/MMF</arm_group_label>
    <arm_group_label>Alefacept QW/Tacrolimus</arm_group_label>
    <arm_group_label>Alefacept QOW/Tacrolimus/MMF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of
             transplant procedure

          -  Subject is a recipient of a de novo kidney transplant

          -  Subject is a recipient of a kidney from a non-human leukocyte antigen (HLA) identical
             related living donor, a non-related living donor, or a deceased donor

        Exclusion Criteria:

          -  Subject has a screening (pre-operative)estimated cluster of differentiation (CD) 4+
             T-cell count of &lt; 250 cells/ÂµL

          -  Subject will receive a kidney with an anticipated cold ischemia time (CIT) of &gt; 30
             hours

          -  Recipient has a positive T or B-cell cross match by investigational site's standard
             method of determination

          -  Subject will receive a kidney from a 50-65 year old deceased donor with one of the
             following:

               -  History of hypertension and a terminal serum creatinine &gt; 1.5 mg/dL

               -  Cerebrovascular accident as cause of death and a terminal serum creatinine &gt; 1.5
                  mg/dL

               -  History of hypertension and cerebrovascular accident as cause of death and a
                  terminal serum creatinine &gt; 1.5 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent/National Institute of Transplantation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research/Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Science Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, Shands Hospital, Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia, Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush - Presbyterian - St. Lukes Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo General Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Transplant Services</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital - Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital Research Institute of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University School of Medicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=407</url>
    <description>Link to results on JAPIC</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <results_first_submitted>November 6, 2015</results_first_submitted>
  <results_first_submitted_qc>November 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2015</results_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>alefacept</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Alefacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled de novo kidney transplant recipients who were at least 18 years of age.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus/MMF/Basiliximab</title>
          <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Alefacept QW/Tacrolimus/MMF</title>
          <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Alefacept QW/Tacrolimus</title>
          <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="P4">
          <title>Alefacept QOW/Tacrolimus/MMF</title>
          <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous Reasons</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but never received study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus/MMF/Basiliximab</title>
          <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Alefacept QW/Tacrolimus/MMF</title>
          <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Alefacept QW/Tacrolimus</title>
          <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Alefacept QOW/Tacrolimus/MMF</title>
          <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="78"/>
            <count group_id="B5" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.44" spread="15.077"/>
                    <measurement group_id="B2" value="49.26" spread="13.532"/>
                    <measurement group_id="B3" value="47.80" spread="12.469"/>
                    <measurement group_id="B4" value="49.68" spread="13.749"/>
                    <measurement group_id="B5" value="48.80" spread="13.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review</title>
        <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Day 182 was used for the analyses at 6 months. Lost to follow-up or patients with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review</title>
          <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Day 182 was used for the analyses at 6 months. Lost to follow-up or patients with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="6.5" upper_limit="18.9"/>
                    <measurement group_id="O2" value="26.3" lower_limit="18.0" upper_limit="34.6"/>
                    <measurement group_id="O3" value="18.8" lower_limit="11.4" upper_limit="26.3"/>
                    <measurement group_id="O4" value="16.7" lower_limit="9.8" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The aim of this study was to assess the non-inferiority of each experimental arm (Arms 2-4) to a comparator regimen (Arm 1) over a non-inferiority margin of 10%. If the upper bound of the 90% confidence interval was less than the margin, i.e., 10%, then the test treatment was considered to be non-inferior to the comparator regimen.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>13.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.2</ci_lower_limit>
            <ci_upper_limit>23.9</ci_upper_limit>
            <estimate_desc>A positive difference indicates a higher failure rate in the experimental arm as compared to the comparator arm (Arm 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The aim of this study was to assess the non-inferiority of each experimental arm (Arms 2-4) to a comparator regimen (Arm 1) over a non-inferiority margin of 10%. If the upper bound of the 90% confidence interval was less than the margin, i.e., 10%, then the test treatment was considered to be non-inferior to the comparator regimen.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>6.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
            <estimate_desc>A positive difference indicates a higher failure rate in the experimental arm as compared to the comparator arm (Arm 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The aim of this study was to assess the non-inferiority of each experimental arm (Arms 2-4) to a comparator regimen (Arm 1) over a non-inferiority margin of 10%. If the upper bound of the 90% confidence interval was less than the margin, i.e., 10%, then the test treatment was considered to be non-inferior to the comparator regimen.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>4.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
            <estimate_desc>A positive difference indicated a higher failure rate in the experimental arm as compared to the comparator arm (Arm 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival at Month 6 and Month 12</title>
        <description>Patient survival is any participant who is known to be alive 6 months and 12 months after the skin closure date.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival at Month 6 and Month 12</title>
          <description>Patient survival is any participant who is known to be alive 6 months and 12 months after the skin closure date.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="92.7" upper_limit="99.7"/>
                    <measurement group_id="O2" value="94.8" lower_limit="90.6" upper_limit="99.0"/>
                    <measurement group_id="O3" value="97.3" lower_limit="94.3" upper_limit="100.0"/>
                    <measurement group_id="O4" value="93.6" lower_limit="89.0" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="81.2" upper_limit="93.5"/>
                    <measurement group_id="O2" value="92.2" lower_limit="87.2" upper_limit="97.2"/>
                    <measurement group_id="O3" value="87.8" lower_limit="81.5" upper_limit="94.1"/>
                    <measurement group_id="O4" value="89.7" lower_limit="84.1" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patient survival at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient survival at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patient survival at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patient survival at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient survival at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patient survival at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Survival at Month 6 and Month 12</title>
        <description>Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months and 12 months after the skin closure date. Graft loss was defined as patient death, retransplant, permanent return to dialysis (dialysis greater than 30 days) or transplant nephrectomy.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival at Month 6 and Month 12</title>
          <description>Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months and 12 months after the skin closure date. Graft loss was defined as patient death, retransplant, permanent return to dialysis (dialysis greater than 30 days) or transplant nephrectomy.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="92.7" upper_limit="99.7"/>
                    <measurement group_id="O2" value="93.5" lower_limit="88.9" upper_limit="98.1"/>
                    <measurement group_id="O3" value="96.0" lower_limit="92.3" upper_limit="99.7"/>
                    <measurement group_id="O4" value="92.3" lower_limit="87.3" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="81.2" upper_limit="93.5"/>
                    <measurement group_id="O2" value="90.9" lower_limit="85.5" upper_limit="96.3"/>
                    <measurement group_id="O3" value="86.5" lower_limit="79.9" upper_limit="93.0"/>
                    <measurement group_id="O4" value="85.8" lower_limit="79.2" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Graft survival at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Graft survival at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Graft survival at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Graft survival at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>3.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>11.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Graft survival at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Graft survival at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BCAR at Month 12 Assessed by Local Review</title>
        <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Day 365 was used for the analyses at 12 months. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BCAR at Month 12 Assessed by Local Review</title>
          <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Day 365 was used for the analyses at 12 months. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="8.6" upper_limit="22.1"/>
                    <measurement group_id="O2" value="29.0" lower_limit="20.4" upper_limit="37.6"/>
                    <measurement group_id="O3" value="20.2" lower_limit="12.5" upper_limit="27.9"/>
                    <measurement group_id="O4" value="18.1" lower_limit="10.9" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>13.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>24.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>15.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>12.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BCAR at Month 6 and 12 Assessed by Central Review</title>
        <description>Rejection episodes were confirmed by biopsy by a central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BCAR at Month 6 and 12 Assessed by Central Review</title>
          <description>Rejection episodes were confirmed by biopsy by a central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.7" upper_limit="12.7"/>
                    <measurement group_id="O2" value="18.3" lower_limit="11.0" upper_limit="25.6"/>
                    <measurement group_id="O3" value="12.1" lower_limit="5.9" upper_limit="18.3"/>
                    <measurement group_id="O4" value="14.2" lower_limit="7.7" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.7" upper_limit="12.7"/>
                    <measurement group_id="O2" value="19.7" lower_limit="12.2" upper_limit="27.2"/>
                    <measurement group_id="O3" value="12.1" lower_limit="5.9" upper_limit="18.3"/>
                    <measurement group_id="O4" value="15.5" lower_limit="8.8" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>10.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>6.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>14.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>12.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.0</ci_lower_limit>
            <ci_upper_limit>21.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>7.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>16.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Local Review</title>
        <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Local Review</title>
          <description>Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="6.5" upper_limit="18.9"/>
                    <measurement group_id="O2" value="25.0" lower_limit="16.8" upper_limit="33.1"/>
                    <measurement group_id="O3" value="18.8" lower_limit="11.4" upper_limit="26.3"/>
                    <measurement group_id="O4" value="16.7" lower_limit="9.8" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="7.6" upper_limit="20.5"/>
                    <measurement group_id="O2" value="27.7" lower_limit="19.2" upper_limit="36.1"/>
                    <measurement group_id="O3" value="18.8" lower_limit="11.4" upper_limit="26.3"/>
                    <measurement group_id="O4" value="18.1" lower_limit="10.9" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>12.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>22.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>6.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>13.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.0</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>14.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Central Review</title>
        <description>Rejection episodes were confirmed by biopsy by the central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Central Review</title>
          <description>Rejection episodes were confirmed by biopsy by the central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.
The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.7" upper_limit="12.7"/>
                    <measurement group_id="O2" value="17.0" lower_limit="9.9" upper_limit="24.1"/>
                    <measurement group_id="O3" value="12.1" lower_limit="5.9" upper_limit="18.3"/>
                    <measurement group_id="O4" value="14.2" lower_limit="7.7" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="2.7" upper_limit="12.7"/>
                    <measurement group_id="O2" value="18.4" lower_limit="11.1" upper_limit="25.7"/>
                    <measurement group_id="O3" value="12.1" lower_limit="5.9" upper_limit="18.3"/>
                    <measurement group_id="O4" value="15.5" lower_limit="8.8" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>9.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>6.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>14.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>10.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>T-cell Mediated BCAR at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>7.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>16.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 4 in Glomerular Filtration Rate Estimated by the MDRD Method at Month 6 and Month 12</title>
        <description>The glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) method.</description>
        <time_frame>Week 4, Month 6 and Month 12</time_frame>
        <population>Full analysis set with available data at Week 4. &quot;N&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 4 in Glomerular Filtration Rate Estimated by the MDRD Method at Month 6 and Month 12</title>
          <description>The glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) method.</description>
          <population>Full analysis set with available data at Week 4. &quot;N&quot; indicates the number of participants with available data at each time point.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="17.16"/>
                    <measurement group_id="O2" value="59.3" spread="24.01"/>
                    <measurement group_id="O3" value="51.6" spread="19.32"/>
                    <measurement group_id="O4" value="58.0" spread="16.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6 (N=65, 66, 67, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="16.44"/>
                    <measurement group_id="O2" value="3.2" spread="13.86"/>
                    <measurement group_id="O3" value="8.3" spread="12.96"/>
                    <measurement group_id="O4" value="2.5" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12 (n=66, 64, 64, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="18.88"/>
                    <measurement group_id="O2" value="3.3" spread="16.55"/>
                    <measurement group_id="O3" value="9.1" spread="13.59"/>
                    <measurement group_id="O4" value="2.7" spread="16.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 4 in GFR by Iothalamate Clearance at Month 6</title>
        <description>The glomerular filtration rate was measured directly using iothalamate clearance.</description>
        <time_frame>Week 4 and Month 6</time_frame>
        <population>Full analysis set with available data at Week 4. &quot;N&quot; indicates participants with available data at Week 4 and Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 4 in GFR by Iothalamate Clearance at Month 6</title>
          <description>The glomerular filtration rate was measured directly using iothalamate clearance.</description>
          <population>Full analysis set with available data at Week 4. &quot;N&quot; indicates participants with available data at Week 4 and Month 6.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" spread="26.327"/>
                    <measurement group_id="O2" value="56.51" spread="33.612"/>
                    <measurement group_id="O3" value="44.36" spread="19.045"/>
                    <measurement group_id="O4" value="52.09" spread="25.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6 (N=48, 45, 45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.81" spread="24.298"/>
                    <measurement group_id="O2" value="3.47" spread="34.708"/>
                    <measurement group_id="O3" value="3.56" spread="21.104"/>
                    <measurement group_id="O4" value="6.60" spread="35.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 4 in Serum Creatinine at Month 6 and 12</title>
        <time_frame>Week 4 and Month 6 and 12</time_frame>
        <population>Full analysis set with available data at Week 4. &quot;N&quot; indicates participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 4 in Serum Creatinine at Month 6 and 12</title>
          <population>Full analysis set with available data at Week 4. &quot;N&quot; indicates participants with available data at each time point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.68"/>
                    <measurement group_id="O2" value="1.6" spread="1.25"/>
                    <measurement group_id="O3" value="1.6" spread="0.84"/>
                    <measurement group_id="O4" value="1.5" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6 (N=69, 69, 68, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.64"/>
                    <measurement group_id="O2" value="-0.2" spread="1.08"/>
                    <measurement group_id="O3" value="-0.3" spread="0.64"/>
                    <measurement group_id="O4" value="-0.0" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12 (N=67, 67, 65, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.45"/>
                    <measurement group_id="O2" value="-0.2" spread="1.24"/>
                    <measurement group_id="O3" value="-0.2" spread="0.76"/>
                    <measurement group_id="O4" value="0.1" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Local Review</title>
        <description>Efficacy failure is defined as death, graft failure (permanent return to dialysis [&gt;30 days] or retransplant), BCAR according to local review, or lost to follow-up.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Local Review</title>
          <description>Efficacy failure is defined as death, graft failure (permanent return to dialysis [&gt;30 days] or retransplant), BCAR according to local review, or lost to follow-up.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="8.5" upper_limit="21.8"/>
                    <measurement group_id="O2" value="29.9" lower_limit="21.3" upper_limit="38.4"/>
                    <measurement group_id="O3" value="22.7" lower_limit="14.7" upper_limit="30.6"/>
                    <measurement group_id="O4" value="23.1" lower_limit="15.2" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="17.3" upper_limit="33.4"/>
                    <measurement group_id="O2" value="33.8" lower_limit="24.9" upper_limit="42.6"/>
                    <measurement group_id="O3" value="29.3" lower_limit="20.7" upper_limit="38.0"/>
                    <measurement group_id="O4" value="29.5" lower_limit="21.0" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>14.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>17.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>7.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>8.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Central Review</title>
        <description>Efficacy failure is defined as death, graft failure (permanent return to dialysis [&gt;30 days] or retransplant), BCAR according to central review, or lost to follow-up.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Central Review</title>
          <description>Efficacy failure is defined as death, graft failure (permanent return to dialysis [&gt;30 days] or retransplant), BCAR according to central review, or lost to follow-up.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="5.5" upper_limit="17.3"/>
                    <measurement group_id="O2" value="22.1" lower_limit="14.3" upper_limit="29.9"/>
                    <measurement group_id="O3" value="16.0" lower_limit="9.0" upper_limit="23.0"/>
                    <measurement group_id="O4" value="20.5" lower_limit="13.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="11.7" upper_limit="26.2"/>
                    <measurement group_id="O2" value="26.0" lower_limit="17.8" upper_limit="34.2"/>
                    <measurement group_id="O3" value="21.3" lower_limit="13.6" upper_limit="29.1"/>
                    <measurement group_id="O4" value="25.6" lower_limit="17.5" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>10.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>13.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>9.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>7.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Efficacy Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>6.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First BCAR Assessed by Local Review</title>
        <description>The time to first BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis set with a BCAR assessed by local review</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First BCAR Assessed by Local Review</title>
          <description>The time to first BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.</description>
          <population>Full analysis set with a BCAR assessed by local review</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="194"/>
                    <measurement group_id="O2" value="12" lower_limit="6" upper_limit="301"/>
                    <measurement group_id="O3" value="19" lower_limit="7" upper_limit="195"/>
                    <measurement group_id="O4" value="12.5" lower_limit="5" upper_limit="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First BCAR Assessed by Central Review</title>
        <description>The time to first BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis set with a BCAR as assessed by the central reviewer</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First BCAR Assessed by Central Review</title>
          <description>The time to first BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.</description>
          <population>Full analysis set with a BCAR as assessed by the central reviewer</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="6" upper_limit="142"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="187"/>
                    <measurement group_id="O3" value="12" lower_limit="7" upper_limit="52"/>
                    <measurement group_id="O4" value="11.5" lower_limit="5" upper_limit="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First T-cell Mediated BCAR Assessed by Local Review</title>
        <description>The time to first T-cell mediated BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis set with a T-cell mediated BCAR as assessed by local review</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First T-cell Mediated BCAR Assessed by Local Review</title>
          <description>The time to first T-cell mediated BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.</description>
          <population>Full analysis set with a T-cell mediated BCAR as assessed by local review</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="194"/>
                    <measurement group_id="O2" value="12" lower_limit="6" upper_limit="301"/>
                    <measurement group_id="O3" value="18" lower_limit="7" upper_limit="178"/>
                    <measurement group_id="O4" value="12.5" lower_limit="5" upper_limit="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First T-cell Mediated BCAR Assessed by Central Review</title>
        <description>The time to first T-cell mediated BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a T-cell mediated BCAR are included in the analysis.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis set with a T-cell mediated BCAR as assessed by the central reviewer</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First T-cell Mediated BCAR Assessed by Central Review</title>
          <description>The time to first T-cell mediated BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a T-cell mediated BCAR are included in the analysis.</description>
          <population>Full analysis set with a T-cell mediated BCAR as assessed by the central reviewer</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="6" upper_limit="142"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="187"/>
                    <measurement group_id="O3" value="12" lower_limit="7" upper_limit="52"/>
                    <measurement group_id="O4" value="11.5" lower_limit="5" upper_limit="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Grade of T-cell Mediated Rejection Assessed by Local Review</title>
        <description>The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.
Grade IA: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising &gt;25% of the luminal area; Grade III: Cases with âtransmuralâ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Grade of T-cell Mediated Rejection Assessed by Local Review</title>
          <description>The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.
Grade IA: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising &gt;25% of the luminal area; Grade III: Cases with âtransmuralâ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Grade of T-cell Mediated Rejection as Assessed by Central Review</title>
        <description>The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.
Grade IA: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising &gt;25% of the luminal area; Grade III: Cases with &quot;transmural&quot; arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Grade of T-cell Mediated Rejection as Assessed by Central Review</title>
          <description>The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.
Grade IA: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (&gt; 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising &gt;25% of the luminal area; Grade III: Cases with &quot;transmural&quot; arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Treated Acute Rejection at Month 6 and Month 12</title>
        <description>Patients who received immunosuppressive medications for the treatment of suspected or BCAR were considered to have a clinically-treated acute rejection.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Treated Acute Rejection at Month 6 and Month 12</title>
          <description>Patients who received immunosuppressive medications for the treatment of suspected or BCAR were considered to have a clinically-treated acute rejection.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="11.7" upper_limit="26.2"/>
                    <measurement group_id="O2" value="33.8" lower_limit="24.9" upper_limit="42.6"/>
                    <measurement group_id="O3" value="29.3" lower_limit="20.7" upper_limit="38.0"/>
                    <measurement group_id="O4" value="23.1" lower_limit="15.2" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="12.8" upper_limit="27.7"/>
                    <measurement group_id="O2" value="35.1" lower_limit="26.1" upper_limit="44.0"/>
                    <measurement group_id="O3" value="30.7" lower_limit="21.9" upper_limit="39.4"/>
                    <measurement group_id="O4" value="23.1" lower_limit="15.2" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-lymphocyte-treated Rejection at Months 6 and 12</title>
        <description>Participants with histologically proved Banff Grade II or III rejection could receive anti-rejection therapy with anti-lymphocyte antibodies per institutional protocol.
The use of anti-lymphocyte antibody therapy at any time during a suspected or proven rejection episode for the treatment of acute rejection was considered an event.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-lymphocyte-treated Rejection at Months 6 and 12</title>
          <description>Participants with histologically proved Banff Grade II or III rejection could receive anti-rejection therapy with anti-lymphocyte antibodies per institutional protocol.
The use of anti-lymphocyte antibody therapy at any time during a suspected or proven rejection episode for the treatment of acute rejection was considered an event.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="1.8" upper_limit="10.8"/>
                    <measurement group_id="O2" value="20.8" lower_limit="13.2" upper_limit="28.4"/>
                    <measurement group_id="O3" value="12.0" lower_limit="5.8" upper_limit="18.2"/>
                    <measurement group_id="O4" value="7.7" lower_limit="2.7" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="1.8" upper_limit="10.8"/>
                    <measurement group_id="O2" value="20.8" lower_limit="13.2" upper_limit="28.4"/>
                    <measurement group_id="O3" value="12.0" lower_limit="5.8" upper_limit="18.2"/>
                    <measurement group_id="O4" value="7.7" lower_limit="2.7" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Multiple Rejection Episodes at Months 6 and 12</title>
        <description>All participants were evaluated for the incidence of multiple rejection episodes (clinically treated and/or BCAR as assessed by the local reviewer) through 6 months and 12 months.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Multiple Rejection Episodes at Months 6 and 12</title>
          <description>All participants were evaluated for the incidence of multiple rejection episodes (clinically treated and/or BCAR as assessed by the local reviewer) through 6 months and 12 months.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="3.9" lower_limit="0.3" upper_limit="7.5"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0.3" upper_limit="7.7"/>
                    <measurement group_id="O4" value="2.6" lower_limit="0.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="7.8" lower_limit="2.8" upper_limit="12.8"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0.3" upper_limit="7.7"/>
                    <measurement group_id="O4" value="3.8" lower_limit="0.3" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Failure at Month 6 and 12</title>
        <description>Treatment failure was defined as death, graft loss, BCAR (local review), lost to follow-up or early discontinuation of treatment regimen. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Failure at Month 6 and 12</title>
          <description>Treatment failure was defined as death, graft loss, BCAR (local review), lost to follow-up or early discontinuation of treatment regimen. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="18.4" upper_limit="34.8"/>
                    <measurement group_id="O2" value="37.7" lower_limit="28.6" upper_limit="46.7"/>
                    <measurement group_id="O3" value="38.4" lower_limit="29.0" upper_limit="47.7"/>
                    <measurement group_id="O4" value="29.5" lower_limit="21.0" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="26.6" upper_limit="44.4"/>
                    <measurement group_id="O2" value="45.5" lower_limit="36.1" upper_limit="54.8"/>
                    <measurement group_id="O3" value="45.2" lower_limit="35.7" upper_limit="54.8"/>
                    <measurement group_id="O4" value="34.7" lower_limit="25.8" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>11.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>11.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Failure at Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>10.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>9.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Failure at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>11.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Quality of Life Index Score Over Time</title>
        <description>The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) symptom severity score. The GIQLI is a 36-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past 2 weeks on a scale from 0 (all of the time) to 4 (never). Possible overall scores ranged from 0 to 4, with higher scores indicating a better quality of life according to the different symptomatic criteria.</description>
        <time_frame>Months 1, 3, 6, and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Quality of Life Index Score Over Time</title>
          <description>The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) symptom severity score. The GIQLI is a 36-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past 2 weeks on a scale from 0 (all of the time) to 4 (never). Possible overall scores ranged from 0 to 4, with higher scores indicating a better quality of life according to the different symptomatic criteria.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (N=63, 60, 59, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.602"/>
                    <measurement group_id="O2" value="2.97" spread="0.541"/>
                    <measurement group_id="O3" value="3.00" spread="0.513"/>
                    <measurement group_id="O4" value="2.98" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N=53, 52, 53, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="0.595"/>
                    <measurement group_id="O2" value="3.29" spread="0.441"/>
                    <measurement group_id="O3" value="3.11" spread="0.516"/>
                    <measurement group_id="O4" value="3.16" spread="0.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=58, 61, 57, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="0.589"/>
                    <measurement group_id="O2" value="3.26" spread="0.450"/>
                    <measurement group_id="O3" value="3.24" spread="0.491"/>
                    <measurement group_id="O4" value="3.17" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=62, 60, 52, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="0.524"/>
                    <measurement group_id="O2" value="3.18" spread="0.554"/>
                    <measurement group_id="O3" value="3.26" spread="0.605"/>
                    <measurement group_id="O4" value="3.19" spread="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Symptom Rating Scale Scores Over Time</title>
        <description>The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale Scores (GSRS). The GSRS a 15-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms.</description>
        <time_frame>Months 1, 3, 6, and 12</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;N&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/MMF/Basiliximab</title>
            <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Alefacept QW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Alefacept QW/Tacrolimus</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Alefacept QOW/Tacrolimus/MMF</title>
            <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptom Rating Scale Scores Over Time</title>
          <description>The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale Scores (GSRS). The GSRS a 15-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;N&quot;)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (N=70, 61, 61, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.665"/>
                    <measurement group_id="O2" value="1.43" spread="0.490"/>
                    <measurement group_id="O3" value="1.59" spread="0.674"/>
                    <measurement group_id="O4" value="1.48" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N=58, 55, 53, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.480"/>
                    <measurement group_id="O2" value="1.42" spread="0.672"/>
                    <measurement group_id="O3" value="1.47" spread="0.568"/>
                    <measurement group_id="O4" value="1.34" spread="0.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=63, 67, 62, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.602"/>
                    <measurement group_id="O2" value="1.41" spread="0.695"/>
                    <measurement group_id="O3" value="1.49" spread="0.471"/>
                    <measurement group_id="O4" value="1.42" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=63, 65, 53, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.635"/>
                    <measurement group_id="O2" value="1.42" spread="0.564"/>
                    <measurement group_id="O3" value="1.52" spread="0.609"/>
                    <measurement group_id="O4" value="1.57" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus/MMF/Basiliximab</title>
          <description>Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Alefacept QW/Tacrolimus/MMF</title>
          <description>Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Alefacept QW/Tacrolimus</title>
          <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Alefacept QOW/Tacrolimus/MMF</title>
          <description>Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy Mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Splenic Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Septal Defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Parathyroid Gland Enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Erosive Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Reflux Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum Sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Polyomavirus-Associated Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia Cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Arteriovenous Graft Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bacterial Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>BK Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Catheter Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis Enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis Of Male External Genital Organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Clostridial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Disseminated Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Enterococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Epstein-Barr Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Escherichia Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Escherichia Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fungal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Helicobacter Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Incision Site Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Intertrigo Candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Meningitis Cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oesophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Perinephric Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Peritonitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia Herpes Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia Mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia Pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sepsis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Streptococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Streptococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wound Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications Of Transplanted Kidney</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Therapeutic Agent Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Perirenal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Post Procedural Urine Leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Graft Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Incision Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Transplant Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Anastomotic Leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Histology Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Immunosuppressant Drug Level Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urine Output Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Muscle Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Chronic Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Multiple Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Unresponsive To Stimuli</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Focal Glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nephritis Interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Obstructive Uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Removal Of Renal Transplant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula Operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pancreas Transplant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renovascular Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Catheter Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications Of Transplanted Kidney</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Incision Site Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Incision Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Perinephric Collection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Post Procedural Discharge</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Therapeutic Agent Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wound Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood Magnesium Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood Urea Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>CD4 Lymphocytes Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Immunosuppressant Drug Level Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urine Output Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vitamin D Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vitamin D Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Spasm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Scrotal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Standard Restriction Description: Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 12 months after data-lock, whichever is first. Sponsor must receive a siteâs manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Head Global Medical Sciences--Transplant and Immunology/Inflammation</name_or_title>
      <organization>Astellas Pharma Global Development, Inc. (APGD)</organization>
      <email>Astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

